Sandu [SANDUPHQ] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Sandu Pharmaceuticals, Inc.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Sandu Pharmaceuticals, Inc. wins in 8 metrics, Divi's Laboratories Ltd. wins in 12 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Sandu Pharmaceuticals, Inc. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) 20.68 67.11 Sandu Pharmaceuticals, Inc.
Price-to-Book Ratio 1.00 10.82 Sandu Pharmaceuticals, Inc.
Debt-to-Equity Ratio 1.06 0.58 Divi's Laboratories Ltd.
PEG Ratio 0.27 4.63 Sandu Pharmaceuticals, Inc.
EV/EBITDA 14.48 48.63 Sandu Pharmaceuticals, Inc.
Profit Margin (TTM) 3.06% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) 4.66% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) 4.66% 29.65% Divi's Laboratories Ltd.
Return on Equity 3.69% 14.64% Divi's Laboratories Ltd.
Return on Assets (TTM) 2.78% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $104,000 $2.15B Divi's Laboratories Ltd.
Dividend Yield 1.61% 0.91% Sandu Pharmaceuticals, Inc.
1-Year Return -19.97% -0.43% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 0.63 16.18 Sandu Pharmaceuticals, Inc.
Enterprise Value $388.60M $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 0.58 15.86 Sandu Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 57.96% 63.71% Divi's Laboratories Ltd.
Revenue per Share (TTM) $69 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $2.11 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) 0.07 0.19 Sandu Pharmaceuticals, Inc.

Sandu Pharmaceuticals, Inc. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

SANDUPHQ
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Sandu Pharmaceuticals, Inc.4.57%3.52%13.34%24.67%11.02%14.83%
Divi's Laboratories Ltd.-0.44%1.34%-2.25%8.85%4.11%4.17%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Sandu Pharmaceuticals, Inc.-19.97%-28.02%-9.05%49.41%206.86%307.54%
Divi's Laboratories Ltd.-0.43%85.44%58.15%496.33%1,610.60%10,946.76%

Performance & Financial Health Analysis: Sandu Pharmaceuticals, Inc. vs Divi's Laboratories Ltd.

MetricSANDUPHQDIVISLAB
Market Information
Market Cap i₹421.61M₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i7,699253,443
90 Day Avg. Volume i5,431283,911
Last Close₹43.51₹6,608.50
52 Week Range₹30.00 - ₹58.28₹5,636.50 - ₹7,071.50
% from 52W High-25.34%-6.55%
All-Time High₹86.00 (Apr 25, 2022)₹7,071.50 (Jul 08, 2025)
% from All-Time High-49.41%-6.55%
Growth Metrics
Quarterly Revenue Growth0.02%0.12%
Quarterly Earnings Growth0.76%-0.01%
Financial Health
Profit Margin (TTM) i0.03%0.24%
Operating Margin (TTM) i0.05%0.30%
Return on Equity (TTM) i0.04%0.15%
Debt to Equity (MRQ) i1.060.58
Cash & Liquidity
Book Value per Share (MRQ)₹43.50₹580.95
Cash per Share (MRQ)₹3.85₹122.95
Operating Cash Flow (TTM) i₹5.35M₹19.67B
Levered Free Cash Flow (TTM) i₹15.52M₹21.91B
Dividends
Last 12-Month Dividend Yield i1.61%0.91%
Last 12-Month Dividend i₹0.80₹60.00

Valuation & Enterprise Metrics Analysis: Sandu Pharmaceuticals, Inc. vs Divi's Laboratories Ltd.

MetricSANDUPHQ (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i20.6867.11
Forward P/E iN/A53.75
PEG Ratio i0.274.63
Price to Sales (TTM) i0.6316.18
Price to Book (MRQ) i1.0010.82
Market Capitalization
Market Capitalization i₹421.61M₹1.69T
Enterprise Value i₹388.60M₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i0.5815.86
Enterprise to EBITDA i14.4848.63
Risk & Other Metrics
Beta i0.070.19
Book Value per Share (MRQ) i₹43.50₹580.95

Financial Statements Comparison: Sandu Pharmaceuticals, Inc. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricSANDUPHQ (2025)DIVISLAB (2025)
Revenue/Sales i671.92M93.25B
Cost of Goods Sold i332.04M38.70B
COGS % of Revenue i49.4%41.5%
Gross Profit i339.88M54.55B
Gross Margin i50.6%58.5%
Research & Development i2.33M270.00M
Operating Income (EBIT) i20.94M25.71B
Operating Margin i3.1%27.6%
EBITDA i29.26M33.19B
EBITDA Margin i4.4%35.6%
Pre-Tax Income i21.59M29.16B
Pre-Tax Income % of Revenue i3.2%31.3%
Income Tax i6.07M7.25B
Income Tax % of Revenue i0.9%7.8%
Net Income (Profit) i15.52M21.91B
Profit Margin i2.3%23.5%

Balance Sheet & Liquidity Metrics

MetricSANDUPHQ (2025)DIVISLAB (2025)
Cash & Equivalents i13.04M4.15B
Total Current Assets i262.99M100.81B
Total Current Assets % of Revenue i39.1%108.1%
Total Current Liabilities i120.86M14.52B
Total Current Liabilities % of Revenue i18.0%15.6%
Long-Term Debt i4.19M20.00M
Long-Term Debt % of Revenue i0.6%0.0%
Total Shareholders Equity i420.17M149.69B
Retained Earnings i95.24M134.00B
Retained Earnings % of Revenue i14.2%143.7%
Property, Plant & Equipment i7.46M3.19B

Cash Flow Statement Comparison

MetricSANDUPHQ (2025)DIVISLAB (2025)
Operating Cash Flow i5.35M19.67B
Operating Cash Flow % of Revenue i0.8%21.1%
Capital Expenditures i-9.38M-14.38B
Free Cash Flow i104,0002.15B
FCF Margin i0.0%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricSANDUPHQDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i9.66M265.47M
Float Shares i3.21M117.72M
% Held by Insiders i65.51%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i34.49%19.31%

Dividend Analysis & Yield Comparison: Sandu Pharmaceuticals, Inc. vs Divi's Laboratories Ltd.

MetricSANDUPHQDIVISLAB
Last 12-Month Dividend i₹0.80₹60.00
Last 12-Month Dividend Yield i1.61%0.91%
3-Year Avg Annual Dividend i₹1.02₹50.00
3-Year Avg Dividend Yield i1.12%0.70%
3-Year Total Dividends i₹3.05₹150.00
Ex-Dividend DateSep 19, 2024Jul 25, 2025